Profile

Dr. Yang Yang earned his Ph.D. in Immunology from the Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences in 2021. From 2021 to 2023, he conducted postdoctoral research at the School of Public Health, Shanghai Jiao Tong University School of Medicine, and has been affiliated with the same institution as a faculty member since December 2023. His research focuses on the prevention and therapeutic strategies for chronic liver diseases and liver cancer. Over the past years, he has published over 18 SCI-indexed research articles such as Gut, Nature Communications, Cell Reports Medicine, Journal for Immunotherapy of Cancer, Cardiovascular Diabetology, and Clinical and Translational Medicine.

Grants

• National Natural Science Foundation of China

• China Postdoctoral Science Foundation Special Funding.

• China Postdoctoral Science Foundation General Funding.

Awards & Honors

• the Sailing Program of Shanghai Rising-Star Program

• Shanghai Post-doctoral Excellence Program

Research interests

• Mechanisms and Interventions for Chronic Liver Diseases and Liver Cancer

• Impact of Proactive Healthy Lifestyles on Liver Disease and Cancer Prevention

• Strategies for Active Health Management in Chronic Diseases and Comorbidity Patterns

Publications

• 1. Y. Yang, Pei T, Liu C, Cao M, Hu X, Yuan J, Chen F, Guo B, Hong Y, Liu J, Li B, Li X, Wang H*. Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A⁺ myeloid cells to promote liver cancer progression. Gut. 2025. (First author,IF=23.1)

• 2. Yang Y, Pei T, Hu X, Lu Y, Huang Y, Wan T, Liu C, Chen F, Guo B, Hong Y, Ba Q, Li X, Wang H. Dietary vitamin B3 supplementation induces the antitumor immunity against liver cancer via biased GPR109A signaling in myeloid cell. Cell Reports Medicine. 2024 Sep 17;5(9):101718. (First author,IF=11.7)

• 3. Huang Y, Zhou Y, Xu Y, Wang X, Zhou Z, Wu K, Meng Q, Wang L, Yang Y, Gao H, Ji J, Jiang X, Yang Y*, Hao L, Wang H. Inflammatory markers link triglyceride-glucose index and obesity indicators with adverse cardiovascular events in patients with hypertension: insights from three cohorts. Cardiovascular Diabetology 24, 11 (2025). (Corresponding author,IF=8.5)

• 4. Y. Yang, M. Sun, W. Yao, F. Wang, X. Li, W. Wang, J. Li, Z. Gao, L. Qiu, R. You, C. Yang, Q. Ba, H. Wang, Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. Journal for ImmunoTherapy of Cancer. 2020;8: e000317. (First author,IF=13.751)

• 5. Y. Yang, M. Sun, W. Li, C. Liu, Z. Jiang, P. Gu, J. Li, W. Wang, R. You, Q. Ba, X. Li, H. Wang. Rebalancing TGF-β/Smad7 signaling via Compound kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis. Clinical and Translational Medicine. 2021;11: e410. (First author,IF=11.492)

• 6. C. Liu, Y. Yang, C. Chen, L. Li, J. Li, X. Wang, Q. Chu, L. Qiu, Q. Ba, X. Li, H. Wang. Environmental eustress modulates β-ARs/CCL2 axis to induce anti-tumor immunity and sensitize immunotherapy against liver cancer in mice. Nature Communications, 2021, 12:5725. (co-First author,IF=17.694)

• 7. Y.Yang, Y. Lu, T. Pei, B. Guo, J. Li, H. Wang, Q. Ba. Compound kushen injection in cancer treatments: Efficacy, active ingredients, and mechanisms. Pharmacological Research - Modern Chinese Medicine. 2022; 3:100108. (First author)

• 8. M. Sun, P. Gu, Y. Yang, L. Yu, Z. Jiang, J. Li, Y. Chen, Q. Ba, H. Wang. Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NFκB axis. Journal for ImmunoTherapy of Cancer. 2021; 9:e002508. (co-First author,IF=13.751)

• 9. Huang Y, Xu J, Yang Y, Wan T, Wang H*, Li X*. Association between Lifestyle Modification and All-Cause, Cardiovascular, and Premature Mortality in Individuals with Non-Alcoholic Fatty Liver Disease. Nutrients. 2024 Jun 28;16(13):2063. (co-First author,IF=4.8)